Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Inclusion Criteria:

- Males and Females 30-80 years old

- Use of highly effective methods of contraception during study in women of
childbearing potential

- Outpatients

- Clinical diagnosis of Parkinson's Disease according to UK Parkinson's Disease Society
Brain Bank Clinical Diagnosis criteria

- Score of >/= 2 on UPDRS items 32 and 33

- Dyskinesias for at least 3 months before baseline

- On stable treatment regimen with L-dopa and other anti-parkinsonian treatment for 4
weeks prior to baseline

- Demonstrate capacity to complete accurate diary ratings

- Patients who have a primary caregiver willing to assess the condition of the patient
throughout the study in accordance with protocol requirements

- Group 2 only: Patients must be on a stable and well tolerated dose of amantadine for
at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during
the remainder of the study

Exclusion Criteria:

- Atypical/secondary form of Parkinson's disease

- History of surgical treatment of PD, including deep brain stimulation

- A score of 5 in the "ON"- state on the Modified Hoehn and Yahr scale

- Advanced, severe, or unstable disease other than PD

- Evidence of dementia

- Treatment with certain prohibited medications

- Amantadine within 2 weeks prior to BL1 visit (applies to Group 1 only)

Other protocol-defined inclusion/exclusion criteria may apply.